MentiNova Overview

  • Founded
  • 2012
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $500K
Latest Deal Amount
  • Investors
  • 1

MentiNova General Information


Provider of oral medication treatment services intended to focus on the treatment of Parkinson's disease. The company's treatment targets an important regulatory system in a unique manner through a repurposing approach to control brain circuitry, enabling doctors to cure mental diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • 155 Village Boulevard
  • Suite 130
  • Princeton, NJ 08540
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

MentiNova Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 25-Jan-2013 $500K 00000 Completed Startup
To view MentiNova’s complete valuation and funding history, request access »

MentiNova Executive Team (3)

Name Title Board Seat Contact Info
M. Maral Mouradian MD Co-Founder, Chair of the Board & President
Steven Braithwaite Ph.D Co-Founder
George Heinrich MD Advisor
To view MentiNova’s complete executive team members history, request access »

MentiNova Board Members (2)

Name Representing Role Since
James Golubieski Foundation Venture Capital Group Board Member & Advisor 000 0000
M. Maral Mouradian MD MentiNova Co-Founder, Chair of the Board & President 000 0000
To view MentiNova’s complete board members history, request access »

MentiNova Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Foundation Venture Capital Group Venture Capital Minority 000 0000 000000 0
To view MentiNova’s complete investors history, request access »